MedTrace Logo

KJ-TFC-004 Drug-drug Interaction Study

NCT02967614 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-04-11

No results posted yet for this study

Summary

To assess the pharmacokinetic Interaction between Dorzolamide and Brimonidine in healthy male subjects.

Conditions

Interventions

DRUG

[A]

One eye drop(about 40ul) / Day1 \~ Day8 / BID

DRUG

[B]

One eye drop(about 40ul) / Day1 \~ Day92 / BID

DRUG

[A]+[B](1)

One eye drop(about 40ul) / Day9 \~ Day100 / BID

DRUG

[A]+[B](2)

One eye drop(about 40ul) / Day93 \~ Day100 / BID

Sponsors & Collaborators

  • Kukje Pharma

    lead OTHER

Principal Investigators

  • Kyung-sang Yu, Ph.d., M.B.A · Clinical Trial Center, Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-12-31
Completion
2018-04-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02967614 on ClinicalTrials.gov